LENVIMA® (Lenvatinib)

The FDA on May 13, 2016 approved LENVIMA® capsules in combination with AFINITOR® (Everolimus), for the treatment of advanced Renal Cell Carcinoma following one prior anti-angiogenic therapy. LENVIMA® was first approved in 2015 for the treatment of locally recurrent or metastatic, progressive, RadioActive Iodine-refractory Differentiated Thyroid Cancer. LENVIMA® is a product of Eisai, Inc.